Select Language

ADC Pharmacokinetic Analysis Solutions

Antibody-drug conjugates (ADCs) undergo complex in vivo processes, including deconjugation, payload release, and antibody clearance. Comprehensive PK characterization requires selective analytical approaches to evaluate ADC exposure, payload retention, and in vivo stability.

ACROBiosystems provides analytical reagents and assay development solutions, including payload-specific ADC quantification kits, anti-payload antibodies, anti-idiotypic antibodies, biotinylated proteins, streptavidin reagents, and custom assay services to support preclinical ADC PK studies.

Key Analytes for ADC PK Characterization

Multiple analytes are evaluated during ADC PK studies to characterize systemic exposure, payload retention, and in vivo stability.

Analyte	Measurement	Application
Total Antibody	Conjugated and unconjugated antibody (DAR ≥0)	Evaluate overall antibody exposure and clearance
Conjugated Antibody	Payload-conjugated antibody (DAR ≥1)	Evaluate ADC exposure and payload retention
Total Payload	Conjugated and released payload forms	Evaluate overall payload exposure
Free Payload	Unconjugated payload in circulation	Assess payload release and systemic exposure

Combined analysis of Total Antibody and Conjugated Antibody enables evaluation of ADC exposure, payload retention, and in vivo deconjugation.

Payload-Specific ADC Quantification ELISA Kits

Quantification of conjugated antibody is essential for evaluating ADC exposure and payload retention in PK studies.

ACROBiosystems ADC Quantification ELISA Kits enable payload-specific measurement of MMAE-, MMAF-, and Exatecan-conjugated ADCs in preclinical serum and plasma samples. These kits support ADC PK studies, linker stability evaluation, and assessment of payload retention.

Applications

Application	Purpose
PK Studies	Quantify ADC exposure and support PK parameter analysis, including half-life (t1/2), clearance (CL), and AUC
Toxicokinetic (TK) Studies	Monitor systemic ADC exposure during nonclinical safety studies
Tissue Distribution Studies	Characterize ADC biodistribution profiles and evaluate in vivo distribution patterns
Linker Evaluation	Assess payload retention and evaluate linker stability
Candidate Selection & Developability Assessment	Compare ADC candidates with different payloads, linkers, DAR values, and conjugation strategies

Validated in cynomolgus monkey serum and plasma matrices.

Key Features

Payload-Specific ADC Quantification
Enables selective detection of payload-conjugated ADCs with minimal cross-reactivity.

Reliable Analytical Performance
R² >0.999, intra-assay CV <6%, and inter-assay CV <7%.

Ready-to-Use ELISA Format
Pre-coated plates and complete reagents enable a 2.5-hour workflow.

Validated Assay Performance
Verified for linearity, precision, accuracy, recovery, and specificity.

Assay Principle

Kit Components

Example: MMAE-ADC Quantification ELISA Kit(Cat. No. PKA-A001)

ID	Components	Size
PKA001-C01	Pre-coated Anti-MMAE Antibody Microplate	1 plate (8×12 strips)
PKA001-C02	MMAE-ADC Standard	20 μg
PKA001-C03	HRP-Anti-Human-IgG-Fc Antibody	20 μg
PKA001-C04	10×Washing Buffer	50 mL
PKA001-C05	2×Dilution Buffer	50 mL
PKA001-C06	Substrate Solution	12 mL
PKA001-C07	Stop Solution	7 mL

Click to View Full Product List

Additional Reagents and Services for ADC PK Assay Development

Beyond ADC Quantification ELISA Kits, ACROBiosystems provides reagents and services to support ADC PK assay development, PK characterization, and immunogenicity assessment.

Anti-Payload Antibodies

ACROBiosystems anti-payload antibodies enable payload-specific detection and support assay development across ADC programs.

Key Features

Broad Payload Coverage: Available for major ADC payload classes, including MMAE, MMAF, DXd, and PBD.

Validated in ADC Assays: Verified performance in representative ADC assay formats.

Multiple Formats: Available in unconjugated, biotinylated, and HRP-conjugated formats.

Clone Panels: Multiple clones support screening and antibody pair selection.

Consistent Performance: Evaluated for inter-batch consistency and cross-reactivity.

Anti-Idiotypic Antibodies and Development Services

Anti-idiotypic antibodies

Anti-idiotypic antibodies specifically recognize the variable region of therapeutic antibodies and are valuable tools for drug-specific PK assays and immunogenicity assessment.

ACROBiosystems provides highly specific anti-idiotypic antibodies and customized development services to support ADC PK assay development throughout the drug development process.

Applications

Scenario	Application
PK Assay Development	Support drug-specific concentration measurement and in vivo exposure evaluation.
Immunogenicity Assessment	Support ADA assay development and immunogenicity assessment.
Bioanalytical Method Development	Enable the development and optimization of analytical platforms, including bridging assays, sandwich ELISAs, and related formats.

Anti-Idiotypic Antibody Development Services

Customized services are available from antigen preparation through monoclonal and polyclonal anti-idiotypic antibody generation and PK/ADA assay kit development.

Service

Product Portfolio

Performance Validation & Application Examples

ADC Quantification ELISA Kit Validation

Method performance

Payload Specificity Evaluation

Payload-specific antibodies selectively detect ADCs containing the corresponding payload, with minimal cross-reactivity toward ADCs bearing alternative payload classes.

Anti-MMAE/MMAF antibody (Cat. No. MME-M5252) demonstrates specific recognition of MMAE- and MMAF-conjugated ADCs, with no significant cross-reactivity observed toward DXd-, SN-38-, or DM1-conjugated ADCs.

Request Protocol

Standard Curve Performance

The Exatecan-ADC Quantification ELISA Kit (Cat. No. PKA-A003) demonstrates excellent linearity across the validated concentration range, supporting quantitative analysis of ADC samples.

For each experiment, a standard curve should be generated for each microplate. The absolute OD values may vary depending on the laboratory, operator, or equipment. The example data provided below are for reference only.

Representative PK Assay Applications

Anti-Payload Antibody-Based PK Assays

Quantitative PK assays for RC48 and trastuzumab deruxtecan in serum samples.

Immobilized Mouse Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-M5252) at 5 μg/mL, add Disitamab Vedotin (RC48) in the 50% Mouse serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).

Request Protocol

Immobilized Human Her2, His Tag (Cat. No. HE2-H5225) at 1 μg/mL, add Trastuzumab Deruxtecan in the 100% Human Serum and then add Biotinylated Anti-DXD Antibody, Mouse IgG1, Avitag (Cat. No. DXD-BVM807) at 0.05 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).

Request Protocol

High affinity with ADCs verified by ELISA

Immobilized ADC-DXD at 1 μg/mL (100 μL/well) can bind Mouse Anti-DXD&Exatecan Antibody, Mouse IgG1, mAb (Cat. No. DXD-M684) with a linear range of 0.1-4 ng/mL (Routinely tested).

Request Protocol

Immobilized Disitamab Vedotin (RC48) at 0.2 μg/mL (100 μL/well) can bind Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (Cat. No. MME-M5252) with a linear range of 0.1-2 ng/mL (QC tested).

Request Protocol

Anti-Idiotypic Antibody Develpmnet Case study

Custom Anti-Idiotypic Antibody Enables Sensitive ADC PK Quantification

Naked F(ab′)₂ was used for immunization to generate anti-idiotypic antibodies. The selected anti-idiotypic antibody was paired with Mouse Anti-MMAE Antibody, Mouse IgG1 (MALS verified; Cat. No. MME-M5252) to establish a drug-specific ADC PK assay. Detection was performed using HRP-conjugated streptavidin, achieving a sensitivity of 0.69 ng/mL.

Request Protocol

Related Products

ADC Development Solutions Anti-Payload Antibodies Anti-Idiotypic Antibodies Anti-Idiotypic Antibody Development Services Streptavidin Products Biotinylated Proteins

Resources

Webinar playback and appointment

‘ADC Potency Analysis and Quality Control Technology Breakthrough’ Webinar Series

ACROBiosystems proudly presents the flagship 'ADC Potency Analysisand Quality Control Technology Breakthrough' live webinar series. This series will systematicallydeconstruct critical aspects ofADC drug development through five coremodules-from potency analysis to quality control technologiesempowering breakthroughs in ADC therapeutics by overcoming keytechnical bottlenecks.

Watch Now

Addressing Challenges in Antibody-Drug Conjugate Development

Here is the brief recap of the webinar:ADCs have the potential to enable 'precision medicine' with a wide market reach.Challenges in ADCs include managing Target Affinity, enhancing payload conjugation, and assessing Payload Delivery in vivo Pharmacokinetics. We can provide high-quality solutions to address these challenges.

Watch Now

Building the Perfect Antibody-based Therapeutic from Selection to Engineering and Manufacturing

In this webinar, discover how advanced techniques such as Al-driven candidate selection optimization of antibody sequences, and precise conjugation methods come together to address some of the current challenges in antibody-based therapeutics.